iRhythm Technologies Inc (IRTC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

GuruFocus.com10-31

Revenue: $147.5 million, representing 18.4% year-over-year growth. Gross Margin: 68.8% for the third quarter. Adjusted Operating Expenses: $143.8 million, up 34.3% year-over-year. Adjusted Net Loss: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479941722?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/z2IfA09TKMChqRjkSNnTIA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/502a39b74979a5cee8b14bd37f76d9d2","is_english":true,"pubTime":"2024-10-31 15:16","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479941722","market":"us","top_or_hot":-1,"title":"iRhythm Technologies Inc (IRTC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $147.5 million, representing 18.4% year-over-year growth.\nGross Margin: 68.8% for the third quarter.\nAdjusted Operating Expenses: $143.8 million, up 34.3% year-over-year.\nAdjusted Net Loss: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/irhythm-technologies-inc-irtc-q3-071618021.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iRhythm Technologies Inc (IRTC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niRhythm Technologies Inc (IRTC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 15:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/irhythm-technologies-inc-irtc-q3-071618021.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $147.5 million, representing 18.4% year-over-year growth.\nGross Margin: 68.8% for the third quarter.\nAdjusted Operating Expenses: $143.8 million, up 34.3% year-over-year.\nAdjusted Net Loss: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/irhythm-technologies-inc-irtc-q3-071618021.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRTC","symbol_name":"Irhythm Technologies Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/irhythm-technologies-inc-irtc-q3-071618021.html","article_id":"2479941722","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/z2IfA09TKMChqRjkSNnTIA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/502a39b74979a5cee8b14bd37f76d9d2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479941722","pubTimestamp":1730358978,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Adjusted Operating Expenses: $143.8 million, up 34.3% year-over-year.Adjusted Net Loss: Approximately $39.2 million or a loss of $1 per share.Adjusted EBITDA: Negative $19.9 million or negative 13.5% of revenue.2024 Revenue Guidance: $582.5 million to $587.5 million.2024 Adjusted EBITDA Margin Guidance: Negative 2% to negative 1.5% of full-year revenues.GuruFocus has detected 5 Warning Signs with IRTC.For the complete transcript of the earnings call, please refer to the full earnings call transcript.iRhythm Technologies Inc  reported $147.5 million in revenue for the third quarter of 2024, representing an 18.4% growth year over year.The company achieved record demand from existing accounts and a record number of new account openings, indicating strong market traction.iRhythm Technologies Inc  celebrated its one millionth patient registered for the ZO monitor, showcasing the product's widespread adoption.The company received FDA clearance for the first of two 510 submissions related to ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IRTC":"Irhythm Technologies Inc."},"translate_title":"iRhythm Technologies Inc(IRTC)2024年第三季度收益看涨期权亮点：收入强劲增长...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRTC":1},"content_text":"Revenue: $147.5 million, representing 18.4% year-over-year growth.\nGross Margin: 68.8% for the third quarter.\nAdjusted Operating Expenses: $143.8 million, up 34.3% year-over-year.\nAdjusted Net Loss: Approximately $39.2 million or a loss of $1 per share.\nAdjusted EBITDA: Negative $19.9 million or negative 13.5% of revenue.\nCash and Short-term Investments: Approximately $522 million.\n2024 Revenue Guidance: $582.5 million to $587.5 million.\n2024 Gross Margin Guidance: 68.5% to 69%.\n2024 Adjusted EBITDA Margin Guidance: Negative 2% to negative 1.5% of full-year revenues.\n\n\nWarning! GuruFocus has detected 5 Warning Signs with IRTC.\n\nRelease Date: October 30, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\niRhythm Technologies Inc (NASDAQ:IRTC) reported $147.5 million in revenue for the third quarter of 2024, representing an 18.4% growth year over year.\nThe company achieved record demand from existing accounts and a record number of new account openings, indicating strong market traction.\niRhythm Technologies Inc (NASDAQ:IRTC) celebrated its one millionth patient registered for the ZO monitor, showcasing the product's widespread adoption.\nThe company received FDA clearance for the first of two 510(k) submissions related to its Z system, indicating progress in regulatory compliance.\nInternational expansion efforts are underway, with commercial launches in Austria, the Netherlands, Switzerland, and Spain, as well as regulatory approval in Japan.\n\n Negative Points \n\niRhythm Technologies Inc (NASDAQ:IRTC) is facing significant challenges with ongoing and legacy quality and regulatory issues, including a 2023 FDA warning letter and recent 483 observations.\nThe company is voluntarily delaying regulatory submissions for its ZCT system, pushing the expected filing to the third quarter of 2025.\nIncremental legal and consulting fees related to FDA remediation efforts and DOJ subpoena activities are expected to cost approximately $11 million to $13 million in 2024.\nAdjusted net loss for the third quarter of 2024 was approximately $39.2 million, compared to a loss of $24.1 million in the third quarter of 2023.\nThe delay in the MCT product submission is expected to impact revenue growth, as it was anticipated to contribute significantly in 2025.\n\n Q & A Highlights \nQ: Can you provide more details on the decision to delay the ZAT or MCT approval and how much of this was influenced by the FDA? A: Quentin Blackford, President and CEO, explained that the decision was entirely proactive and voluntary by iRhythm. It was made to ensure a robust submission that aligns with the FDA's expectations, especially after the 483 observations. The company aims to bolster the submission to preemptively address potential questions from the FDA.\nQ: With the guidance implying a strong step-up in the fourth quarter, what gives you confidence in achieving this despite a softer third quarter? A: Daniel Wilson, Executive Vice President, highlighted the strong momentum in the business, driven by record new account openings and balanced growth across both XT and AT products. This setup provides confidence in achieving the fourth-quarter guidance.\nQ: Can you discuss the profile of new accounts and expectations for volume growth into 2025? A: Daniel Wilson noted that the profile of new accounts is consistent with past wins, with some large accounts requiring longer ramp-up times due to EHR integration. The company expects continued volume growth, although the MCT delay will impact the 2025 revenue outlook.\nQ: Could you elaborate on the BioIntelliSense licensing agreement and its commercial aspirations? A: Quentin Blackford expressed excitement about the partnership, which aims to incorporate multisensor capabilities into iRhythm's products. This strategic move is expected to enhance the ACM space and potentially disrupt the hospital-to-home setting, although it is a few years out.\nQ: How are the international expansions, particularly in the UK and Japan, expected to contribute to offsetting the MCT delay? A: Quentin Blackford highlighted the excitement around international markets, especially Japan, where commercial launch is anticipated in the first half of 2025. While these markets will contribute incrementally, the company is cautious about projecting immediate large-scale impacts.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479941722"}